Carlisle MA, Fudim M, DeVore AD, Piccini JP. Heart failure and Atrial Fibrillation, like fire and fury. JACC Heart Fail. 2019;7(6):447–56.
Verma A, Kalman JM, Callans DJ. Treatment of patients with Atrial Fibrillation and Heart failure with reduced ejection fraction. Circulation. 2017;135(16):1547–63.
Article CAS PubMed Google Scholar
Allessie M, Ausma J, Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res. 2002;54(2):230–46.
Article CAS PubMed Google Scholar
Bacmeister L, Schwarzl M, Warnke S, Stoffers B, Blankenberg S, Westermann D, Lindner D. Inflammation and fibrosis in murine models of heart failure. Basic Res Cardiol. 2019;114(3):19.
Nattel S. Ionic determinants of atrial fibrillation and Ca2 + channel abnormalities: cause, consequence, or innocent bystander? Circ Res. 1999;85(5):473–6.
Article CAS PubMed Google Scholar
Mogensen UM, Jhund PS, Abraham WT, Desai AS, Dickstein K, Packer M, Rouleau JL, Solomon SD, Swedberg K, Zile MR, et al. Type of Atrial Fibrillation and Outcomes in patients with heart failure and reduced ejection fraction. J Am Coll Cardiol. 2017;70(20):2490–500.
Cheng M, Lu X, Huang J, Zhang J, Zhang S, Gu D. The prognostic significance of atrial fibrillation in heart failure with a preserved and reduced left ventricular function: insights from a meta-analysis. Eur J Heart Fail. 2014;16(12):1317–22.
Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, D’Agostino RB, Murabito JM, Kannel WB, Benjamin EJ. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation. 2003;107(23):2920–5.
Butt JH, Docherty KF, Jhund PS, de Boer RA, Bohm M, Desai AS, Howlett JG, Inzucchi SE, Kosiborod MN, Martinez FA, et al. Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. Eur J Heart Fail. 2022;24(3):513–25.
Article CAS PubMed Google Scholar
Ponikowski P, Alemayehu W, Oto A, Bahit MC, Noori E, Patel MJ, Butler J, Ezekowitz JA, Hernandez AF, Lam CSP, et al. Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the VICTORIA trial. Eur J Heart Fail. 2021;23(8):1300–12.
Article CAS PubMed Google Scholar
Buchta P, Kalarus Z, Mizia-Stec K, Myrda K, Skrzypek M, Ga Sior M. De novo and pre-existing atrial fibrillation in acute coronary syndromes: impact on prognosis and cardiovascular events in long-term follow-up. Eur Heart J Acute Cardiovasc Care. 2021;10(10):1129–39.
Huang G, Xu JB, Liu JX, He Y, Nie XL, Li Q, Hu YM, Zhao SQ, Wang M, Zhang WY, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers decrease the incidence of atrial fibrillation: a meta-analysis. Eur J Clin Invest. 2011;41(7):719–33.
Thein PM, White K, Banker K, Lunny C, Mirzaee S, Nasis A. Preoperative use of oral Beta-adrenergic blocking agents and the incidence of New-Onset Atrial Fibrillation after Cardiac surgery. A systematic review and Meta-analysis. Heart Lung Circ. 2018;27(3):310–21.
Alexandre J, Dolladille C, Douesnel L, Font J, Dabrowski R, Shavit L, Legallois D, Funck-Brentano C, Champ-Rigot L, Ollitrault P, et al. Effects of Mineralocorticoid receptor antagonists on Atrial Fibrillation occurrence: a systematic review, Meta-analysis, and Meta-Regression to identify modifying factors. J Am Heart Assoc. 2019;8(22):e013267.
Article PubMed PubMed Central Google Scholar
Swedberg K, Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Shi H, Vincent J, Pitt B, Investigators E-HS. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (eplerenone in mild patients hospitalization and SurvIval Study in Heart failure) study. J Am Coll Cardiol. 2012;59(18):1598–603.
Article CAS PubMed Google Scholar
Neefs J, van den Berg NWE, Krul SPJ, Boekholdt SM, de Groot JR. Effect of spironolactone on Atrial Fibrillation in patients with heart failure with preserved ejection Fraction: post-hoc analysis of the Randomized, Placebo-Controlled TOPCAT trial. Am J Cardiovasc Drugs. 2020;20(1):73–80.
Article CAS PubMed Google Scholar
Kaze AD, Zhuo M, Kim SC, Patorno E, Paik JM. Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis. Cardiovasc Diabetol. 2022;21(1):47.
Article CAS PubMed PubMed Central Google Scholar
Scisciola L, Cataldo V, Taktaz F, Fontanella RA, Pesapane A, Ghosh P, Franzese M, Puocci A, De Angelis A, Sportiello L, et al. Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: data from basic science and clinical trials. Front Cardiovasc Med. 2022;9:1008922.
Article CAS PubMed PubMed Central Google Scholar
Zhao Z, Jin P, Zhang Y, Hu X, Tian C, Liu D. SGLT2 inhibitors in Diabetic Patients with Cardiovascular Disease or at High Cardiovascular risk: a systematic review and Meta-analysis of Randomized controlled trials. Front Cardiovasc Med. 2022;9:826684.
Article CAS PubMed PubMed Central Google Scholar
Sfairopoulos D, Liu T, Zhang N, Tse G, Bazoukis G, Letsas K, Goudis C, Milionis H, Vrettos A, Korantzopoulos P. Association between sodium-glucose cotransporter-2 inhibitors and incident atrial fibrillation/atrial flutter in heart failure patients with reduced ejection fraction: a meta-analysis of randomized controlled trials. Heart Fail Rev 2022.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Rev Esp Cardiol (Engl Ed). 2021;74(9):790–9.
Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, et al. The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
Article PubMed PubMed Central Google Scholar
Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol. 2001;54(10):1046–55.
Article CAS PubMed Google Scholar
Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med. 2006;25(20):3443–57.
DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction [serial online]. Accessed November 27., 2022. https://clinicaltrials.gov/ct2/show/NCT03877237.
DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction [serial online]. Accessed November 27., 2022. https://clinicaltrials.gov/ct2/show/NCT03877224.
Dapagliflozin in PRESERVED Ejection Fraction Heart Failure (PRESERVED-HF) [serial online]. Accessed November 27., 2022. https://clinicaltrials.gov/ct2/show/NCT03030235.
Nassif ME, Windsor SL, Tang F, Khariton Y, Husain M, Inzucchi SE, McGuire DK, Pitt B, Scirica BM, Austin B, et al. Dapagliflozin Effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF Trial. Circulation. 2019;140(18):1463–76.
Article CAS PubMed Google Scholar
This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms (EMPERIAL-Reduced) [serial online]. Accessed November 27., 2022. https://clinicaltrials.gov/ct2/show/NCT03448419.
This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms (EMPERIAL-perserved) [serial online]. Accessed November 27., 2022. https://clinicaltrials.gov/ct2/show/NCT03448406.
Butler J, Anker SD, Filippatos G, Khan MS, Ferreira JP, Pocock SJ, Giannetti N, Januzzi JL, Pina IL, Lam CSP, et al. Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. Eur Heart J. 2021;42(13):1203–12.
Article CAS PubMed PubMed Central Google Scholar
Huynh K. Empagliflozin improves clinical outcomes for HFpEF in EMPEROR-Preserved. Nat Rev Cardiol. 2021;18(11):737.
Lee MMY, Brooksbank KJM, Wetherall K, Mangion K, Roditi G, Campbell RT, Berry C, Chong V, Coyle L, Docherty KF, et al. Effect of Empagliflozin on Left ventricular volumes in patients with type 2 diabetes, or Prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation. 2021;143(6):516–25.
Article CAS PubMed Google Scholar
Li W, Chen X, Xie X, Xu M, Xu L, Liu P, Luo B. Comparison of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide receptor agonists for Atrial Fibrillation in type 2 diabetes Mellitus: systematic review with Network Meta-analysis of Randomized controlled trials. J Cardiovasc Pharmacol. 2022;79(3):281–8.
Article CAS PubMed Google Scholar
Zhang Y, Wang J, Jiang L, Wang T, Li Z, Fu X, Huang W, Xiao Y, Wang S, Zhao J. Network meta-analysis on the efficacy and safety of finerenone versus SGLT2 inhibitors on reducing new-onset of atrial fibrillation in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetol Metab Syndr. 2022;14(1):156.
Article PubMed PubMed Central Google Scholar
Sossalla S, Kallmeyer B, Wagner S, Mazur M, Maurer U, Toischer K, Schmitto JD, Seipelt R, Schondube FA, Hasenfuss G, et al. Altered na(+) currents in atrial fibrillation effects of ranolazine on arrhythmias and contractility in human atrial myocardium. J Am Coll Cardiol. 2010;55(21):2330–42.
Article CAS PubMed Google Scholar
Mason FE, Pronto JRD, Alhussini K, Maack C, Voigt N. Cellular and mitochondrial mechanisms of atrial fibrillation. Basic Res Cardiol. 2020;115(6):72.
Article CAS PubMed PubMed Central Google Scholar
Ren X, Wang X, Yuan M, Tian C, Li H, Yang X, Li X, Li Y, Yang Y, Liu N, et al. Mechanisms and treatments of oxidative stress in Atrial Fibrillation. Curr Pharm Des. 2018;24(26):3062–71.
留言 (0)